ストックスクリーナーアプリを入手
1.07
4.46%
-0.05
前日終値:
$1.12
開ける：
$1.13
24時間の取引高:
4.27M
Relative Volume:
0.67
時価総額：
$223.25M
収益：
$52.29M
当期純損益:
$-134.84M
株価収益率:
-1.4267
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
-8.55%
1か月 パフォーマンス:
-5.31%
6か月 パフォーマンス:
+22.29%
1年 パフォーマンス:
-13.36%
1日の値動き範囲:
$1.05
$1.165
1週間の範囲:
$1.05
$1.2383
52週間の値動き範囲:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
名前
Sangamo Therapeutics Inc
セクター
電話
(510) 970-6000
住所
501 CANAL BLVD., RICHMOND, CA
SGMO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
1.07 | 223.25M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | アップグレード | Truist | Hold → Buy |
| 2024-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-01-07 | 再開されました | Guggenheim | Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-12-16 | 再開されました | H.C. Wainwright | Buy |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | SunTrust | Buy |
| 2019-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-10-10 | 開始されました | Guggenheim | Buy |
| 2018-06-20 | 開始されました | BofA/Merrill | Buy |
| 2017-11-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2016-11-01 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-10-19 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-10-23 | 再開されました | Jefferies | Buy |
| 2013-05-03 | 開始されました | BioLogic Equity Research | Sell |
| 2011-02-23 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-07-29 | 繰り返されました | Wedbush | Outperform |
| 2009-10-19 | 開始されました | Brean Murray | Sell |
| 2009-10-07 | 繰り返されました | Leerink Swann | Outperform |
| 2009-08-25 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Sangamo Therapeutics Inc (SGMO) 最新ニュース
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha
Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com Nigeria
Sangamo reports positive Fabry disease gene therapy results - MSN
Sangamo reports updated data for gene therapy candidate ST-920 - MSN
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace
Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St
Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
HC Wainwright Has Bearish Forecast for SGMO FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
5 Best Stem Cell Companies to Invest In (February 2025) - Securities.io
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - The Eastern Progress Online
Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright - Defense World
Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts - Benzinga
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Truist Financial Has Lowered Expectations for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $5.17 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 - MarketBeat
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Q3 2018 First Look: Dancing With Data (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey
Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire
Sangamo Therapeutics Inc (SGMO) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):